4BASEBIO PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,070 GBX | -4.46% |
|
+3.38% | +57.35% |
| 04-10 | 4basebio to supply synthetic DNA for mRNA vaccine program | AN |
| 04-10 | 4Basebio plc Announces the Supply of Its opDNA? DNA Products into Tier 1 Pharma Client's Vaccine Program | CI |
| Sales 2023 * | 500K 625K 50M | Sales 2024 * | 2M 2.5M 200M | Capitalization | 137M 171M 13.7B |
|---|---|---|---|---|---|
| Net income 2023 * | -7M -8.75M -700M | Net income 2024 * | -7M -8.75M -700M | EV / Sales 2023 * | 260 x |
| Net cash position 2023 * | 7.2M 9M 720M | Net cash position 2024 * | 15.1M 18.88M 1.51B | EV / Sales 2024 * | 61 x |
| P/E ratio 2023 * |
-17.8
x | P/E ratio 2024 * |
-17.8
x | Employees | 78 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 30.4% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -4.46% | ||
| 1 week | +3.38% | ||
| Current month | +11.46% | ||
| 1 month | +11.46% | ||
| 3 months | +62.12% | ||
| 6 months | +109.80% | ||
| Current year | +57.35% |
1 week
1 050.00
1 120.00
1 month
901.001 120.00
Current year
640.001 120.00
1 year
492.001 120.00
3 years
330.001 120.00
5 years
175.001 120.00
10 years
175.001 120.00
| Managers | Title | Age | Since |
|---|---|---|---|
Heikki Lanckriet
CEO | Chief Executive Officer | 47 | 21/12/20 |
David John Roth
DFI | Director of Finance/CFO | 56 | 21/12/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Joseph Fernández
BRD | Director/Board Member | 64 | - |
David John Roth
DFI | Director of Finance/CFO | 56 | 21/12/20 |
| Director/Board Member | 53 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1,070 | -4.46% | 2,239 |
| 25/04/24 | 1,120 | +4.67% | 849 |
| 24/04/24 | 1,070 | +2.39% | 3,229 |
| 23/04/24 | 1,045 | 0.00% | 96 |
| 22/04/24 | 1,045 | +0.97% | 1,418 |
Delayed Quote London S.E., April 26, 2024 at 04:35 pm
More quotes
4basebio PLC is a United Kingdom-based specialist life sciences company. It is focused on therapeutic deoxyribonucleic (DNA) for cell and gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. It is engaged in the manufacturing and supplying of application specific synthetic DNA for research, therapeutic and pharmacological use and develop non-viral vectors for the efficient delivery of payloads. It has technology in the fields of DNA synthesis and payload delivery, which enables it to manufacture both synthetic DNA constructs and messenger ribonucleic acid (mRNA) and develop vectors for cell and tissue-specific delivery for a range of applications. Its applications include AAV and Lentivirus viral vectors; mRNA vaccines and therapeutics, Genome editing; DNA vaccines, and Hermes non-viral delivery. It is also focused on exploiting intellectual property in the field of cell and gene therapies and DNA vaccines.
Calendar
07/05/2024
- Q4 2023 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +57.35% | 171M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- 4BB Stock
